Disclosures: Jane Giang: Nothing to Disclose, Sophia Hurr: Nothing to Disclose, Alfred Barritt IV: Merck (Any division): Advisor, Madrigal: Consultant, Life Edit: Consultant, Boehringer Ingelheim: Consultant, Target-RWE: Consultant 1673 ASSESSING TRANSITIONS OF CARE AMONGST INPATIENTS WITH CIRRHOSIS DISCHARGED FROM A DIVERSE, URBAN LIVER TRANSPLANT CENTER: THE IMPORTANCE OF HEPATOLOGY INVOLVEMENT AND DISCHARGE DESTINATION Max Schechter 1 Katherine Ni 2 Zoe Verzani 3 Kimberline Chew 2 Jang Hyun Kim 2 Lewis Paulino 2 Danielle Garfunkel 2 Lital Aliasi-Sinai 4 Daniel Alvarez 2 Adejoke Johnson 2 Soaptarshi Paul 2 Hamza Sadhra 2 Clara Tow 2 Don Rockey 2 , 1 Albert Einstein College of Medicine, 2 Montefiore Medical Center, 3 Weill Cornell Medicine, 4 American Medical Prgm Tel Aviv Universit Background: Hospitalized patients with cirrhosis are at risk of readmission due to the severity and complexity of their disease

In the action in diabetes and vascular disease (ADVANCE) trial, a study involving 11,140 subjects with T2DM who were followed for a median duration of 4.4 years, a higher HR was associated with a significantly increased risk of all-cause mortality, cardiovascular death, and major cardiovascular events (death, nonfatal acute myocardial infarction [AMI] or nonfatal stroke) [39]
It is also not appropriate for everyone, including minors, pregnant or breastfeeding women, and individuals with health conditions who have not consulted a doctor
Brittney joined the firm in May 2022 and does an outstanding job
SGLT2i use was associated with a significantly increased risk of DKA (RR 2.08 [95% CI 1.05, 4.12] p =0.0309)